Semaglutide

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Obesity, Childhood

Conditions

Obesity, Childhood

Trial Timeline

Jan 1, 2027 → Jan 31, 2032

NCT ID

NCT06977438

About Semaglutide

Semaglutide is a approved stage product being developed by Novo Nordisk for Obesity, Childhood. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06977438. Target conditions include Obesity, Childhood.

What happened to similar drugs?

20 of 20 similar drugs in Obesity, Childhood were approved

Approved (20) Terminated (5) Active (0)

✅exenatide + PlaceboEli LillyApproved

✅TirzepatideEli LillyApproved

✅Micafungin + MicafunginAstellas PharmaApproved

✅MicafunginAstellas PharmaApproved

✅Zonegran + PlaceboEisaiApproved

✅lorcaserin hydrochloride XR + PlaceboEisaiApproved

✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06977438	Approved	Recruiting	Jan 1, 2027	Jan 31, 2032	Obesity, Childhood
NCT05689372	Pre-clinical	Recruiting	Feb 28, 2026	May 31, 2027	Diabetes Mellitus, Type 2
NCT05714683	Pre-clinical	Recruiting	Dec 31, 2025	Oct 30, 2026	Diabetes Mellitus, Type 2
NCT07055607	Pre-clinical	Recruiting	Nov 21, 2025	Aug 15, 2028	Obesity
NCT07280221	Pre-clinical	Recruiting	Nov 10, 2025	Oct 31, 2027	Obesity
NCT07081178	Pre-clinical	Recruiting	Aug 8, 2025	Oct 21, 2027	Obesity
NCT06571383	Approved	Active	Sep 17, 2024	Nov 15, 2031	Obesity
NCT06507475	Pre-clinical	Completed	Sep 7, 2024	Dec 20, 2024	Diabetes Mellitus, Type 2
NCT06478550	Pre-clinical	Completed	Jun 26, 2024	Apr 23, 2025	Diabetes Mellitus, Type 2
NCT06283667	Pre-clinical	Recruiting	Jun 11, 2024	Jan 31, 2028	Obesity
NCT06351748	Pre-clinical	Completed	Jan 2, 2024	Mar 29, 2024	Diabetes Mellitus, Type 2
NCT06097390	Phase 1	Completed	Sep 28, 2023	Mar 27, 2024	Healthy Participants
NCT05996874	Phase 1	Completed	Aug 12, 2023	Apr 18, 2024	Healthy Participants
NCT05755360	Pre-clinical	Completed	Feb 21, 2023	Oct 21, 2024	Diabetes Mellitus, Type 2
NCT05716724	Pre-clinical	Completed	Jan 25, 2023	Jul 9, 2023	Diabetes Mellitus, Type 2
NCT05443191	Pre-clinical	Completed	Oct 20, 2022	Apr 27, 2023	Diabetes Mellitus, Type 2
NCT05443334	Pre-clinical	Completed	Jul 28, 2022	Jul 4, 2024	Diabetes Mellitus, Type 2
NCT05468632	Pre-clinical	Completed	Jul 5, 2022	Jul 31, 2022	Diabetes Mellitus, Type 2
NCT05533632	Approved	Completed	Apr 25, 2022	Jan 18, 2024	Diabetes Mellitus, Type 2
NCT05316662	Pre-clinical	Completed	Apr 6, 2022	Apr 6, 2024	Diabetes Mellitus, Type 2

Competing Products

20 competing products in Obesity, Childhood

See all competitors

Product	Company	Stage	Hype Score
MK0493	Merck	Phase 2	35
MK0557	Merck	Phase 3	40
AMG 786	Amgen	Phase 1	29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo	Eli Lilly	Phase 2	39
Tirzepatide	Eli Lilly	Phase 2	42
exenatide + Placebo	Eli Lilly	Approved	43
Brenipatide	Eli Lilly	Phase 1	36
Orforglipron + Placebo	Eli Lilly	Phase 3	47
TERN-601	Terns Pharmaceuticals	Phase 2	32
MBX 4291 + Placebo	MBX Biosciences	Phase 1	30
PG-102	Rani Therapeutics	Phase 1	26
Orforglipron + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
Eloralintide + Placebo	Eli Lilly	Phase 1	29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo	Eli Lilly	Phase 2	27
LY3437943 + Midazolam + Warfarin + Caffeine	Eli Lilly	Phase 1	29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection	Skye Bioscience	Phase 2	29
Tirzepatide	Eli Lilly	Approved	50
Adenosine + Regadenoson	Astellas Pharma	Pre-clinical	26
Micafungin + Micafungin	Astellas Pharma	Approved	43